uniQure N.V. (QURE): EBITDA
-$170.59M
Year ended 2025-12-31
-$178.55M
Trailing 12 months to 2026-03-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$170.59M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$171.65M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$270.97M | n/m | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | -$134.62M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $317.92M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$114.78M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$114.47M | n/m | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | -$75.82M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$63.80M | n/a | 2020-03-02, From 2017-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | -$170.59M | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$79.91M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$278.0K | n/m |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | -$7.43M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$123.80M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$80.47M | n/m |
| Scynexis Inc (SCYX) | 2024-12-31 | -$37.12M | n/m |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$43.81M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $270.0K | n/m |
Compare QURE, PYXS, CVSI, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗